Literature DB >> 27504013

Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation.

Kristine Færch1, Dorte Vistisen2, Giovanni Pacini3, Signe S Torekov4,5, Nanna B Johansen2,6, Daniel R Witte6,7, Anna Jonsson4, Oluf Pedersen4, Torben Hansen4, Torsten Lauritzen7, Marit E Jørgensen2, Bo Ahrén8, Jens Juul Holst4,5.   

Abstract

Hyperinsulinemia is an adaptive mechanism that enables the maintenance of normoglycemia in the presence of insulin resistance. We assessed whether glucagon is also involved in the adaptation to insulin resistance. A total of 1,437 individuals underwent an oral glucose tolerance test with measurements of circulating glucose, insulin, and glucagon concentrations at 0, 30 and 120 min. Early glucagon suppression was defined as suppression in the period from 0 to 30 min, and late glucagon suppression as 30 to 120 min after glucose intake. Insulin sensitivity was estimated by the validated insulin sensitivity index. Individuals with screen-detected diabetes had 30% higher fasting glucagon levels and diminished early glucagon suppression, but greater late glucagon suppression when compared with individuals with normal glucose tolerance (P ≤ 0.014). Higher insulin resistance was associated with higher fasting glucagon levels, less early glucagon suppression, and greater late glucagon suppression (P < 0.001). The relationship between insulin sensitivity and fasting glucagon concentrations was nonlinear (P < 0.001). In conclusion, increased fasting glucagon levels and delayed glucagon suppression, together with increased circulating insulin levels, develop in parallel with insulin resistance. Therefore, glucose maintenance during insulin resistance may depend not only on hyperinsulinemia but also on the ability to suppress glucagon early after glucose intake.
© 2016 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27504013     DOI: 10.2337/db16-0240

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  52 in total

Review 1.  Mechanisms of Insulin Action and Insulin Resistance.

Authors:  Max C Petersen; Gerald I Shulman
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

2.  Islet isograft transplantation improves insulin sensitivity in a murine model of type 2 diabetes.

Authors:  Monica Young Choi; Seong Jun Lim; Mi Joung Kim; Yu-Mee Wee; Hyunwook Kwon; Chang Hee Jung; Young Hoon Kim; Duck Jong Han; Sung Shin
Journal:  Endocrine       Date:  2021-03-12       Impact factor: 3.633

3.  Impaired Insulin Action Is Associated With Increased Glucagon Concentrations in Nondiabetic Humans.

Authors:  Anu Sharma; Ron T Varghese; Meera Shah; Chiara Dalla Man; Claudio Cobelli; Robert A Rizza; Kent R Bailey; Adrian Vella
Journal:  J Clin Endocrinol Metab       Date:  2018-01-01       Impact factor: 5.958

4.  Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids.

Authors:  Nicolai J Wewer Albrechtsen; Kristine Færch; Troels M Jensen; Daniel R Witte; Jens Pedersen; Yuvaraj Mahendran; Anna E Jonsson; Katrine D Galsgaard; Marie Winther-Sørensen; Signe S Torekov; Torsten Lauritzen; Oluf Pedersen; Filip K Knop; Torben Hansen; Marit E Jørgensen; Dorte Vistisen; Jens J Holst
Journal:  Diabetologia       Date:  2018-01-05       Impact factor: 10.122

5.  Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice.

Authors:  Gina Song; Giovanni Pacini; Bo Ahrén; David Z D'Argenio
Journal:  Peptides       Date:  2016-12-21       Impact factor: 3.750

6.  Glucose metabolism during rotational shift-work in healthcare workers.

Authors:  Anu Sharma; Marcello C Laurenti; Chiara Dalla Man; Ron T Varghese; Claudio Cobelli; Robert A Rizza; Aleksey Matveyenko; Adrian Vella
Journal:  Diabetologia       Date:  2017-05-27       Impact factor: 10.122

7.  Fasting glucagon concentrations are associated with longitudinal decline of β-cell function in non-diabetic humans.

Authors:  Jon D Adams; Chiara Dalla Man; Marcello C Laurenti; M Daniela Hurtado Andrade; Claudio Cobelli; Robert A Rizza; Kent R Bailey; Adrian Vella
Journal:  Metabolism       Date:  2020-02-08       Impact factor: 8.694

8.  A Hepatocyte FOXN3-α Cell Glucagon Axis Regulates Fasting Glucose.

Authors:  Santhosh Karanth; J D Adams; Maria de Los Angeles Serrano; Ezekiel B Quittner-Strom; Judith Simcox; Claudio J Villanueva; Lale Ozcan; William L Holland; H Joseph Yost; Adrian Vella; Amnon Schlegel
Journal:  Cell Rep       Date:  2018-07-10       Impact factor: 9.423

9.  Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function.

Authors:  Xi Chen; Enrique Maldonado; Ralph A DeFronzo; Devjit Tripathy
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

10.  Assessment of individual and standardized glucagon kinetics in healthy humans.

Authors:  Marcello C Laurenti; Adrian Vella; Jon D Adams; Daniel J Schembri Wismayer; Aoife M Egan; Chiara Dalla Man
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-11-02       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.